Background {#Sec1}
==========

Irritable bowel syndrome (IBS) affects around 10% of adult populations \[[@CR1]\]. IBS might be even more common in patients with morbid obesity \[[@CR2], [@CR3]\]. The core symptom of IBS is frequent abdominal pain associated with changes in bowel habits. The underlying pathophysiology is multifactorial and includes a combination of psychological factors and gut related factors (as changes in motility, inflammation or the gut microbiome) \[[@CR4]\]. The diagnosis IBS is based on symptom-based criteria \[[@CR5]\].

Roux-en-Y gastric bypass (RYGB) is the second most common surgical procedure applied in the treatment of morbid obesity when conservative measures have failed \[[@CR6]\]. RYGB enables a large and sustained weight loss, improvement of obesity-related co-morbidities and health related quality of life (HRQoL), with low risk of surgical complications \[[@CR7]--[@CR9]\]. However, recent reports indicate that abdominal pain is common 2--5 years after RYGB \[[@CR10]--[@CR12]\]. Internal herniation and gallstone related disease are common causes of acute pain, whereas the etiology of chronic abdominal pain after RYGB is less well understood \[[@CR13]--[@CR15]\].

The primary aims of this study were to study the change in the prevalence of IBS-like symptoms from before to 2 years after RYGB and to search for preoperative predictors of these symptoms after RYGB. Furthermore we aimed to study changes in scores of constipation, diarrhea and HRQoL in all participants and in those with and without IBS-like symptoms.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This is a prospective cohort study, where we invited patients with morbid obesity at the obesity centers at Oslo University Hospital (OUH) and Innlandet Hospital Trust Gjøvik (IHT-G), Norway, to participate. Participants who underwent RYGB were invited for a follow-up consultation 2 years after RYGB. Participants at OUH and IHT-G were recruited during February 2014 to June 2015, and December 2012 to September 2014, respectively. Follow-up was completed June 2017 and May 2017 at OUS and IHT-G, respectively. Subject with morbid obesity who previously has failed non-surgical measures of weigh loss were considered eligible for. Morbid obesity was defined as having a body mass index (BMI) ≥ 40 kg/m^2^ or BMI ≥ 35 kg/m^2^ with obesity-related comorbidity. Exclusion criteria for study inclusion were age younger than 18 or older than 60 years, previous bariatric surgery, other indications for RYGB than morbid obesity, simultaneous cholecystectomy, other serious disorders unrelated to obesity (including organic gastrointestinal disorder) and inability to read Norwegian language.

Surgical procedure and study visits {#Sec4}
-----------------------------------

All RYGB operations were performed in a standardized manner, with a laparoscopic approach, a gastric pouch of about 25 ml, a 150 cm antecolic alimentary and a 50 cm biliopancreatic limb \[[@CR16]\]. Mesenteric defects were routinely closed with non-absorbable staplers. Study visits were performed preoperatively and 2 years after RYGB. At study visits, demographics, medical history, and were registered in a predefined case report form. A routine clinical examination was performed including anthropometric measurements, and fasting blood samples were retrieved. If symptoms or clinical examination was susceptive of organic gastrointestinal disorder additional diagnostic evaluations including endoscopic examinations were made according to the clinician's discretion. All patients filled in questionnaires for the classification of IBS, gastrointestinal symptoms and HRQoL.

Outcomes {#Sec5}
--------

Five demographic variables were evaluated: Age (years), gender (male/female), BMI (kg/m^2^), employment status (full time/not working) and cohabitant status (living with partner/not living with partner). Five co-morbid conditions were evaluated: Type 2 diabetes (T2D), hypothyroidism, hypertension, fibromyalgia, and minor psychiatric disorders (anxiety or depression). The information concerning co-morbidity was given by the participant and reviewed by a clinician with full access to the patient's medical record. T2D was defined as HbA~1c~ ≥ 6.5%, or the use of one or more oral glucose lowering drugs, with or without insulin treatment. Diabetes remission was defined as HbA~1c~ \< 6.5% without use of glucose lowering drugs, in a participant with prior T2D.

IBS, IBS-like symptoms, gastrointestinal symptoms and HRQoL {#Sec6}
-----------------------------------------------------------

IBS and IBS-like symptoms were evaluated by the Rome III questionnaire in a validated translation to Norwegian \[[@CR5]\]. Preoperatively participants who fulfilled the Rome III criteria for IBS were classified as having IBS, postoperatively participants who fulfilled the Rome III criteria for IBS were classified as having IBS-like symptoms. Our study protocol did not include supplementary examinations of participants fulfilling the Rome III criteria to explore underlying pathophysiology of IBS or IBS-like symptoms. Rome III evaluates pain and discomfort without differentiating these measures. Furthermore, participants reporting preoperative IBS did not receive any treatment addressing IBS symptoms as part of this study or to our knowledge by others. Thus the presented IBS population likely represents an untreated IBS population. Notably, no restrictions were placed on participants in regard to seeking medical attention for IBS related symptoms.

Symptoms of constipation and diarrhea were evaluated using the Gastrointestinal Symptoms Rating Scale (GSRS). The patients responded using a Likert-type scale (1 = no discomfort and 7 = severe discomfort) \[[@CR17]\]. The GSRS-IBS questionnaire was used at IHT-G, and the GSRS at OUS. Common variables from the two questionnaires were used to calculate the constipation and diarrhea symptom scores reported in this article.

Participants from OUS reported HRQoL at the preoperative and 2 year follow-up visit, participants from IHT-G reported HRQoL only at the 2 year follow-up visit. To evaluate HRQoL the Norwegian validated translation of the 36-Item Short Form Health Survey (SF-36) version 2 was used \[[@CR18]\]. The SF-36 questionnaires were scored using the QualityMetric Health Outcomes™ Scoring Software 4.5 giving eight health domains; physical functioning, physical role functioning, bodily pain, general health perception, vitality, social role functioning, emotional role functioning and mental health, and two summary scores; physical component score and mental component score.

Blood tests {#Sec7}
-----------

The reference values for the fifteen variables reported in the results are as follows: *hemoglobin* g/dL: women 11.7--15.3, men 13.4--17.0; *iron* μmol/L: 9--34; *ferritin* μg/L: women 10--170, men 30--400; *white-cell count* 10^9^/L: 3.5--10.0; *c-reactive protein (CRP)* mg/L: \< 5; *cholesterol* mmol/L: age 18--29 2.9--6.1, age 30--49 3.3--6.9, age \> 50 3.9--7.8; *high-density lipoprotein (HDL)* mmol/L: women 1.0--2.7, men 0.8--2.1; *low-density lipoprotein (LDL)* mmol/L: age 18--29 1.3--4.3, age 30--49 1.5--4.8, age \> 50 2.0--5.4; *triglycerides* mmol/L: 0.5--2.6; *thyroid stimulating hormone (TSH)* mIE/L: 0.5--3.6; *vitamin B*~*1*~ nmol/liter: 95--200; *vitamin B*~*6*~ nmol/liter: 15--160; *vitamin B*~*12*~ pmol/L: 150--650; *folic acid* nmol/L: 7--40; glycosylated *hemoglobin* (*HbA*~*1c*~) %: 4.0--6.0.

Statistical analysis {#Sec8}
--------------------

Paired-sample t--tests or Wilcoxon rank test were used for evaluation of changes in continuous variables between preoperative and 2 year follow-up. McNemar's test for paired proportions was used for evaluation of changes in categorical variables. For comparing subgroups independent sample t-test was used. Missing data for the GSRS item scores was imputed using the mean score of the non-missing items. Patient characteristics associated with IBS-like symptoms were studied by using independent sample t-test, the Chi Square test or Fisher exact test as appropriate.

Logistic regression analysis was performed to identify preoperative predictors of IBS-like symptoms 2 years after RYGB. Any variable associated with *p* \< 0.25 from the univariable analysis were entered into a multivariable logistic regression model using a manual backward stepwise elimination procedure. Centre of inclusion and IBS at baseline were forced into the multivariable model. Multivariable analyses were preceded by estimation of correlation between risk factors. Predictors that correlated \> 0.7, were not included in the model in order to avoid multicollinearity. The association between preoperative characteristics and IBS-like symptoms at the 2 year follow-up visit was quantified by odds ratio (OR) with 95% confidence intervals (CI). Two tailed *p*-values \< 0.05 were considered statistically significant. All statistical analyses were made using the IBM SPSS statistics version 25.0 (IBM SPSS Inc., Armonk, NY: IBM Corp). The results are given as mean with standard deviation (SD) in brackets if not otherwise indicated.

Results {#Sec9}
=======

Of 307 participants operated with RYGB, 240 (78%) attended the 2 year follow-up visit and 233 (76%) filled out the study questionnaires (Fig. [1](#Fig1){ref-type="fig"}). In total 45 (19%) of 233 included participants were operated at IHT-G. Table [1](#Tab1){ref-type="table"} gives the participants' characteristics at the preoperative and the 2 year follow-up visits. Fig. 1Flow chart describing the inclusion of participants Table 1Patient characteristics at the preoperative visit and the 2 year follow-up visit after Roux-en-Y-gastric bypassPreoperative visit\
*n* = 233Two year follow-up visit\
*n* = 233Statistics\
(*p*-values)Gender (male/female)56 (24%)/177 (76%)Age (years)43.5 (9.1)Body mass index (kg/m^2^)42.9 (4.9)29.5 (4.6)**\<0.001**Living with partner161 (71%)172 (76%)**0.03**Full time work130 (58%)127 (56%)0.78Type 2 diabetes55 (24%)18 (8%)**\<0.001**Hypertension98 (43%)34 (15%)**\<0.001**Hypothyroidism22 (10%)24 (10%)0.73Fibromyalgia33 (14%)36 (16%)0.61Self-reported psychiatric disorder40 (17%)37 (16%)0.76Irritable bowel syndrome27 (12%)61 (26%)**\<0.001**IBS-constipation5 (2%)11 (5%)0.15IBS-diarrhea5 (2%)12 (5%)0.09IBS-mixed16 (7%)34 (15%)**0.004**IBS-unsubtyped1 (0.4%)3 (1%)0.63Hemoglobin (g/dl)14.2 (1.1)13.7 (1.1)**\<0.001**Iron (mol/L)15.1 (5.2)19.6 (6.9)**\<0.001**Ferritin104.5 (8--584)115.0 (4--804)0.31White-cell count (×10^9^/liter)7.7 (2.1)6.2 (1.9)**\<0.001**HbA~1c~ (%)5.7 (4.6--14.9)5.2 (4.0--9.7)**\<0.001**C-reactive protein (mg/liter)7.0 (0--50.0)0.6 (0--66.0)**\<0.001**Cholesterol (mmol/liter)4.9 (1.0)4.3 (0.7)**\<0.001**High-density lipoprotein (mmol/liter)1.2 (0.3)1.7 (0.4)**\<0.001**Low-density lipoprotein (mmol/liter)3.2 (0.9)2.5 (0.7)**\<0.001**Triglycerides1.9 (1.3)1.0 (0.5)**\<0.001**Vitamin B~1~ (nmol/liter)157.4 (27.8)159.6 (27.7)0.18Vitamin B~6~ (nmol/liter)36.5 (34.9)52.8 (44.0)**\<0.001**Vitamin B~12~ (pmol/liter)375.8 (166.8)531.4 (321.3)**\<0.001**Folic acid (nmol/liter)20.3 (9.0)22.2 (10.6)**0.014**The results are given as number (proportion in per cent) for categorical variables, mean (SD) for continuous variables with normal distribution and median (min-max) for other variables. Significant *p*-values are marked in boldData were analyzed with McNemar test for categorical variables and paired t-tests or Wilcoxon signed-rank test (marked with†) for continuous variablesFor one patient, we had insufficient information for subtyping of IBS at the 2 year follow-up visitMissing variables: Living with partner (*n* = 7), Full time work (*n* = 7), type 2 diabetes (*n* = 3), Hypertension (*n* = 4) Hypothyroidism (*n* = 4), Fibromyalgia (*n* = 4), minor psychiatric disorder (*n* = 4), Hemoglobin (=2), Iron (*n* = 2), Ferritin (*n* = 7), White-cell count (*n* = 3), HbA1c (n = 2), CRP (*n* = 3), Cholesterol (*n* = 2), High-density lipoprotein (*n* = 2), Low-density lipoprotein (n = 2), Triglycerides (*n* = 2), Vitamin B1 (*n* = 4), Vitamin B6 (*n* = 4), Vitamin B12 (*n* = 2), Folic acid (*n* = 2)\*Two de-novo diabetes mellitus

Prior to the RYGB surgery 27 participants (12%) had IBS, 2 years after surgery 61 (26%) reported IBS-like symptoms (*p* \< 0.001). 11/27 (41%) of those with IBS before RYGB did not report IBS-like symptoms after RYGB. New onset IBS-like symptoms were identified in 45/206 (22%) of participants without IBS preoperatively (Fig. [2](#Fig2){ref-type="fig"}), representing 19% of the total population at the 2 year follow-up visit. Fig. 2Prevalence of Irritable bowel syndrome (IBS) at the preoperative visit and IBS-like symptoms at the 2 year follow-up visit after Roux-en-Y-gastric bypass. IBS status was defined according to the Rome III criteria. The prevalence of symptoms of IBS increased from 12 to 26% (*p* \< 0.001)

Fibromyalgia, low LDL levels, high vitamin B~1~ levels and IBS before RYGB were independent preoperative predictors of IBS-like symptoms at the 2 year follow-up visit (Table [2](#Tab2){ref-type="table"}). Among participants without IBS at the preoperative visit, fibromyalgia and high vitamin B1 levels were independent preoperative predictors of IBS-like symptoms at follow-up (data not shown). Table 2Preoperative predictors of irritable bowel syndrome (IBS)-like symptoms 2 years after Roux-en-Y-gastric bypass (RYGB)Preoperative characteristicsPatients without IBS-like symptoms after RYGB\
*n* = 172Patients with IBS-like symptoms\
after RYGB\
*n* = 61Odds ratio\
(95% CI)Statistics\
(*p*-values)Adjusted for all significant predictors and center of inclusionOdds ratio\
(95% CI)Statistics\
(*p*-values)*Gender (female)127/172 (74%)50/61 (82%)1.6 (0.77--3.4)****0.20***Age (years)43.3 (9.3)43.3 (8.4)1.0 (0.94--1.0)0.66Body mass index (kg/m^2^)42.8 (4.9)43.1 (4.6)1.0 (0.96--1.1)0.65*Living with partner118/171 (69%)47/61 (77%)1.5 (0.77--3.0)****0.24****Working full time105/171 (61%)28/61 (46%)0.53 (0.30--0.96)****0.037***Smokers39/168 (23%)10/59 (17%)0.68 (0.31--1.5)0.32Type 2 diabetes42/172 (24%)15/61 (25%)1.0 (0.51--2.0)0.98Hypertension74/171 (43%)25/61 (40%)0.76 (0.50--1.7)0.76Hypothyroidism14/172 (8%)8/61 (13%)1.7 (0.68--4.3)0.26***Fibromyalgia**16/171 (9%)**17/61 (28%)**3.7 (1.8--8.0)**0.001**4.1 (1.7--9.8)**0.001****Self-reported psychiatric disorder26/172 (15%)14/61 (23%)1.7 (0.81--3.5)****0.17**IBS before RYGB**11/172 (6%)**16/61 (26%)**5.2 (2.6--12.0)**\< 0.001**7.2 (2.8--18.6)**\< 0.001***Hemoglobin (g/dl)14.1 (1.1)14.3 (1.1)1.1 (0.86--1.5)0.41Iron (μmol/L)15.0 (5.3)15.6 (5.1)1.0 (0.97--1.1)0.43Ferritin (μg/L)144 (130.3)138 (103.8)1.0 (0.99--1.0)0.74White-cell count (×10^9^/liter)7.6 (2.1)7.7 (2.1)1.0 (0.88--1.8)0.83HbA~1~C (%)6.1 (1.4)6.0 (1.4)0.94 (0.75--1.8)0.58*Thyroid stimulating hormone (x10E-3 IU/L)1.7 (0.95)2.2 (1.9)1.3 (1.0--1.7)****0.039***C-reactive protein (mg/liter)7.7 (6.3)7.7 (5.5)1.0 (0.95--1.1)0.99Cholesterol (mmol/liter)5.0 (1.0)4.8 (0.95)0.82 (0.61--1.1)0.20\*High-density lipoprotein (mmol/liter)1.2 (0.31)1.2 (0.25)0.86 (0.32--2.4)0.77***Low-density lipoprotein (mmol/liter)**3.2 (0.92)**3.0 (0.75)**0.81 (0.58--1.1)**0.20**0.66 (0.45--0.96)**0.031***Triglycerides (mmol/L)1.86 (1.4)1.88 (1.2)1.0 (0.81--1.3)0.93***Vitamin B***~***1***~ ***(nmol/liter)**155 (28.1)**162 (27.2)**1.0 (0.99--1.0)**0.11**1.0 (1.0--1.0)**0.013***Vitamin B~6~ (nmol/liter)36.6 (36.9)36.0 (27.9)1.0 (0.99--1.0)0.91*Vitamin B*~*12*~ *(pmol/liter)384 (182)350 (110)1.0 (1.0--1.0)****0.17***Folic acid (nmol/liter)20.0 (9.0)20.9 (8.8)1.0 (0.98--1.0)0.50The results are given as number (proportion in per cent) for categorical variables, and mean (SD) for continuous variables with normal distribution. Preoperative characteristics associated with IBS-like symptoms 2 years after RYGB were studied with univariate regression. Any variable associated from the univariate analysis (with p \< 0.25) were entered into a multivariable logistic regression model using a manual backward stepwise elimination procedure. In total, 10 potential predictors were examined in the multivariable analysis (*p*-values written in bold). Cholesterol was not included in the final analysis due to high correlation with LDL

Symptom scores for constipation at the preoperative and 2 year follow-up visits were 1.5 (0.9) and 1.8 (1.2) (*p* \< 0.001), and for diarrhea 1.4 (0.9) and 1.8 (1.1) (*p* \< 0.001), respectively. Table [3](#Tab3){ref-type="table"} shows the changes in constipation and diarrhea scores in all participants, and stratified by IBS status. The most pronounced worsening of constipation and diarrhea symptom scores was found in the groups without IBS before RYGB and the group with new onset IBS-like symptoms after RYGB. Table 3Changes in constipation and diarrhea symptom scores from preoperatively to 2 years after Roux-en-Y Gastric bypass (RYGB)GroupnΔ constipation symptom score95% CI*p*-valuenΔ diarrhea symptom score95% CI*p*-valueAll participants174−0.29−0.44 to −0.14**\<0.001**177−0.40−0.58 to −0.22**\<0.001**Subgroups based on IBS status preoperatively: With IBS21−0.19−0.66 to 0.280.4121−0.38−1.1 to 0.340.28 Without IBS153−0.31−0.46 to −0.15**\<0.001**156−0.40−0.58 to −0.22**\<0.001**Subgroups based on IBS like symptoms 2 years after RYGB: Never IBS or IBS-like symptoms116−0.16−0.32 to 0.0120.068119−0.31−0.50 to − 0.11**0.002** New onset IBS-like symptoms37−0.77−1.13 to − 0.42**\<0.001**37− 0.71− 1.15 to − 0.27**0.002** IBS preoperatively and IBS-like symptoms at 2 year follow-up visit14− 0.24− 0.75 to 0.280.3414− 0.24− 1.3 to 0.780.62All participants, and subgroups based on status of irritable bowel syndrome (IBS) are presented. Significant *p*-values are marked in boldThe presented delta values: Gastrointestinal Symptom Rating Scale (GSRS) at the 2 year follow-up visit - GSRS at the preoperative visit. Positive delta values indicate improved symptoms after RYGB, negative delta values indicate worsened symptoms after RYGB. The results are given as mean values with 95% confidence intervals (CI). Data were analyzed with paired t-testsNew onset IBS: no IBS preoperatively, but IBS-like symptoms 2 years after RYGB. Never IBS: No IBS preoperatively or IBS-like symptoms 2 years after RYGBMissing data Δ constipation symptom score: All participants; *n* = 59. Subgroups based on IBS status preoperatively: with IBS; *n* = 6, without IBS; *n* = 53. Subgroups based on IBS-like symptoms 2 years after RYGB: never IBS or IBS-like symptoms; *n* = 45, new onset IBS-like symptoms; *n* = 8, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; *n* = 2Missing data Δ diarrhea symptom score: All participants; *n* = 56. Subgroups based on IBS status preoperatively: with IBS; *n* = 6, without IBS; *n* = 50, never IBS; *n* = 42. Subgroups based on IBS-like symptoms 2 years after RYGB: new onset IBS-like symptoms; *n* = 8, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; *n* = 2

Prior to RYGB, HRQoL was comparable between participants with and without IBS. At the 2 year follow-up visit participants with IBS-like symptoms had significantly lower HRQoL scores in all eight health domains and both summary scores compared to participants without IBS-like symptoms (Fig. [3](#Fig3){ref-type="fig"}). In participants with and without IBS at the preoperative visit, the improvements in the mean physical component score were 0.54 (12.8) and 7.6 (10.6) (*p* = 0.047) respectively and mental component scores decreased with 1.2 (10.7) and 2.6 (8.2) (p 0.67) respectively. Table [4](#Tab4){ref-type="table"} shows the changes in physical component score and mental component score in all participants and subgroups. Fig. 3Health related quality of life in participants with and without irritable bowel syndrome (IBS) and IBS-like symptoms, before and 2 years after Roux-en-Y gastric bypass (RYGB) Table 4Changes in Physical Component Scores (PCS) and Mental Component Scores (MCS) from preoperatively to two year after Roux-en-Y Gastric bypass (RYGB)Group (number of participants)nΔ PCS95% CI*p*-valueΔ MCS95% CI*p*-valueAll participants1537.15.4 to 8.8**\<0.001**−1,25−2.9 to 0.440.15Subgroups based on IBS at preoperative visit: With IBS100.54−8.6 to 9.70.90−2.6−8.5 to 3.20.33 Without IBS1437.65.8 to 9.3**\<0.001**−1.2−2.9 to 0.620.20Subgroups based on IBS-like symptoms 2 years after RYGB: Never IBS or IBS-like symptoms1137.685.8 to 9.6**\<0.001**0.29−1.5 to 2.10.75 New onset IBS-like symptoms307.152.8 to 11.5**0.002**−6.59−11.3 to − 1.9**0.007** IBS at preoperative and IBS-like symptoms 2 year follow-up visit6−3.3−14.1 to 7.50.47−4.9−14.8 to 5.00.26All participants, and subgroups based on status of irritable bowel syndrome (IBS) are presented. Significant *p*-values are marked in boldThe SF-36 questionnaires were scored using the QualityMetric Health Outcomes™ Scoring Software 4.5 giving the presented Physical Component Scores (PCS) and Mental Component Scores (MCS)The presented delta values: SF-36 value at the 2 year follow-up visit - SF-36 value at the preoperative visit. Positive delta values indicate improved score after RYGB and negative values indicate worsened score after RYGB. The results are given as mean values with 95% confidence intervals (CI). Data were analyzed with paired t-testsNew onset IBS-like symptoms: no IBS before RYGB, but IBS-like symptoms 2 years after RYGB. Never IBS or IBS-like symptoms: No IBS before or IBS-like symptoms 2 years after RYGBMissing data: All participants; *n* = 80. Subgroups based on IBS at preoperative visit: with IBS; *n* = 17, without IBS; *n* = 63. Subgroups based on IBS-like symptoms 2 years after RYGB: never IBS or IBS-like symptoms; *n* = 48, new onset IBS-like symptoms; *n* = 15, IBS at preoperative and IBS-like symptoms 2 year follow-up visit; *n* = 10

Discussion {#Sec10}
==========

The prevalence of IBS-like symptoms more than doubled 2 years after RYGB. IBS-like symptoms thus appears to be a relevant contributing factor for chronic abdominal pain and symptoms after RYGB. It has been hypothesized that low-grade inflammation could be an important cause of IBS in patients with morbid obesity \[[@CR19]\]. In our study, the prevalence of IBS-like symptoms increased in a period where obesity-related inflammation decreased for the majority of participants, weakening this hypothesis.

Participants with preoperative fibromyalgia had four times higher odds of IBS-like symptoms after RYGB than participants without fibromyalgia. Fibromyalgia and IBS may share similar pain processing dysfunctions, such as reduced pain inhibition and aberrant autonomic nervous system responses \[[@CR20]--[@CR22]\]. The considerable weight reduction and the associated reduction of various obesity related symptoms after RYGB may impact the weighting of different bodily sensations (Table [1](#Tab1){ref-type="table"}), and thus in combination with altered gastrointestinal physiology may affect the prevalence of perceived IBS-like symptoms.

Unexpectedly, high levels of vitamin B~1~ before RYGB was an independent preoperative predictor of IBS-like symptoms 2 year post surgery. This finding may be a proxy indicating a specific diet used by these patients or it may be a statistical type 1 bias. The finding should be further explored in future studies.

Participants with lower LDL at the preoperative visit had higher probability of IBS-like symptoms at the 2 year follow-up visit. Previous reports note an association between *higher* LDL and IBS both in subjects with and without obesity \[[@CR23], [@CR24]\]. RYGB induces structural changes in gastrointestinal tract, affects the regulation of several gut hormones including those involved in hunger and satiety, and has been shown to affect the responses of the cerebral frontoparietal control network involved in food preference regulation and non-food cues \[[@CR25]--[@CR27]\]. The net effect is decreased intake of food, enhanced satiety responses and a shift in food preferences from high-energy to low-energy. The pathophysiology of IBS before RYGB could thus differ from that of IBS-like symptoms post RYGB. In subjects with morbid obesity, before surgery, IBS may be more related to the diet or the lipid metabolism \[[@CR24]\], while after RYGB IBS-like symptoms could be more related to disturbances in pain perception and altered gastrointestinal physiology.

Both constipation and diarrhea symptoms increased after RYGB, with a comparable mean change in participants with and without IBS at the preoperative visit. Previous studies have shown diverging dynamics of these symptoms after RYGB \[[@CR12], [@CR28], [@CR29]\]. However, although statistically significant, the absolute changes in mean diarrhea and constipation symptom score are unlikely to be of high clinically importance (\< 15% increase in symptom score), with exception of the subgroup of participants with new onset of IBS-like symptoms after RYGB who experienced a mean 33% increase for both diarrhea and constipation symptom scores.

The observed improvements in the physical functioning aspects of HRQoL after RYGB have previously been described \[[@CR9], [@CR12]\]. However, we are the first to describe that the improved physical functioning is irrespective of the presence of IBS-like symptoms after RYGB. Participants with and without IBS at the preoperative visit had comparable HRQoL. This was surprising, but may be due to the limited number of participants with IBS and HRQoL data available before surgery. After RYGB participants with IBS-like symptoms had significantly lower HRQoL than participants without such symptoms, in line with previous reports \[[@CR30]\].

Of the 206 participants without IBS preoperatively 45 (22%) had new onset IBS-like symptoms 2 years after surgery. This group had a larger increase in diarrhea and constipation symptom scores and a decrease in the mental component score of SF-36 after RYGB. These findings supports an association between IBS-like symptoms after RYGB and worsened psychosocial functioning, and highlight the impact IBS-like symptoms may have on patients' lives after RYGB \[[@CR31]\]. The high rate of IBS-like symptoms after surgery and the reduced HRQoL associated with such symptoms should be part of the preoperative information to patients eligible for bariatric surgery and a clinical focus during follow-up, including guidance in how to reduce symptoms.

Participants with IBS before surgery had seven times higher odds for IBS-like symptoms 2 years after RYGB than those without IBS prior to surgery. However, in participants with IBS preoperatively we observed unchanged HRQoL after RYGB. And it is worth to point out that of the 27 participants with IBS preoperatively 11 (41%) no longer had IBS-like symptoms 2 years after RYGB. Therefore, IBS prior to RYGB should not be considered as an absolute contraindication for surgery.

The large numbered cohort, the high rate of follow up, and the prospective design are important strengths of our study compared to earlier reports. The use of a validated translation of the Rome III and the SF-36 questionnaires and the comprehensive evaluation of all participants are other strengths.

This study contains several major limitations. The study did not differentiate between the different functional abdominal pain syndromes. Participants fulfilling the Rome III criteria for IBS were not systematically examined for underlying pathophysiology of IBS-like symptoms. To what extent the altered physiology or other aspects of the surgical procedure itself contributed to the increase in bowel symptoms could not be answered by this study. In particular, evaluation of small intestinal bacterial overgrowth would be relevant in the evaluation of symptoms. Reporting on the use of medication at follow-up may have added information relevant for interpretation of our findings, particularly medications affecting gastrointestinal function. A control group consisting of patients undergoing other abdominal surgery could add information relevant to the interpretation of our findings.

The large number of variables imposes a risk of type 1 statistical errors. Correction for multiple testing was not performed, but all analyzed variables are presented transparently. Only participants from OUS were evaluated with SF-36 preoperatively. Gastrointestinal symptoms were evaluated with two subtypes of GSRS, thus limiting the study to only report diarrhea and constipation symptom scores for which questions in the two questionnaires were identical. A more precise diagnosis of psychiatric disorders could have strengthened the study.

Blood tests were analyzed at two local laboratories. However for paired sample tests a difference between the laboratories would not affect the results, as all patients were seen at the same center at the preoperative and the 2 year follow-up visits.

Conclusions {#Sec11}
===========

The prevalence of IBS-like symptoms more than doubled and was associated with reduced HRQoL after RYGB. Preoperative IBS and fibromyalgia were strong predictors of such symptoms 2 years after RYGB, yet most of the patients with IBS-like symptoms after surgery had new onset of symptoms.

BMI

:   Body mass index

CRP

:   C-reactive protein

GSRS

:   Gastrointestinal Symptoms Rating Scale

HbA~1c~

:   Glycosylated hemoglobin

HDL

:   High-density lipoprotein

HRQoL

:   Health related quality of life

IBS

:   Irritable bowel syndrome

IHT-G

:   Innlandet Hospital Trust Gjøvik

LDL

:   Low-density lipoprotein (LDL)

OUH

:   Oslo University Hospital

RYGB

:   Roux-en-Y gastric bypass

SF-36

:   36-Item Short Form Health Survey (SF-36)

T2D

:   Type 2 diabetes

TSH

:   Thyroid stimulating hormone
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